Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Green Tea and Quercetin With Docetaxel in mCRPC
NCT06615752Phase 2Recruiting
- Sponsor
- Charles Drew University of Medicine & Science
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of green tea extract, quercetin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Charles Drew University of Medicine & Science. Started Oct 2026; status: recruiting.
02
Drugs
green tea extractquercetin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06615752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615752.